Japan Tissue Engineering CoTSE:7774 -0.32%60 Gross Margin % is 61.20% as of Mar. 2026, which is 6% above its 10-year median of 57.70. GuruFocus rates TSE:7774 with a GF Score™ of 60/100 and a GF Value™ of 円517.18 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 730 Biotechnology companies, Japan Tissue Engineering Co ranks worse than 52.6% on this metric.
Japan Tissue Engineering Co (TSE:7774) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Japan Tissue Engineering Co had a gross margin of 61.20% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Japan Tissue Engineering Co Gross Margin % Related Terms
Japan Tissue Engineering Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7774 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Japan Tissue Engineering Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Japan Tissue Engineering Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Japan Tissue Engineering Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Japan Tissue Engineering Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Japan Tissue Engineering Co (TSE:7774) has a Gross Margin % of 61.20% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Japan Tissue Engineering Co and its competitors. This is near median its historical median of 57.70. Over the past decade, Japan Tissue Engineering Co's Gross Margin % has ranged from 51.25 to 67.24. According to the industry distribution chart, Japan Tissue Engineering Co ranks #384 out of 730 companies in the Biotechnology industry, placing it in the top 52.6%.
Is Japan Tissue Engineering Co's Gross Margin % too high?
Japan Tissue Engineering Co's current Gross Margin % of 61.20% is near median its 10-year median of 57.70. Over the past 10 years, this metric has ranged from a low of 51.25 to a high of 67.24. The Biotechnology industry median Gross Margin % is 60.91. Japan Tissue Engineering Co's value of 61.20% is 0.5% above this industry median. Based on the distribution chart, Japan Tissue Engineering Co ranks #384 out of 730 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Japan Tissue Engineering Co has a GF Score™ of 60/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Japan Tissue Engineering Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Japan Tissue Engineering Co ranks #384 out of 730 companies for Gross Margin %. This places Japan Tissue Engineering Co in the lower half of its industry. The industry median Gross Margin % is 60.91. Japan Tissue Engineering Co's value of 61.20% is 0.5% above this benchmark. Historically, Japan Tissue Engineering Co's own Gross Margin % has ranged from 51.25 to 67.24 over the past decade. While the company's 10-year median is 57.70 vs. the industry median of 60.91, Japan Tissue Engineering Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 730 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Japan Tissue Engineering Co's current Gross Margin % of 61.20% is 0.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Japan Tissue Engineering Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Japan Tissue Engineering Co's current Gross Margin % is 61.20%, which is near median its own 10-year median of 57.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Japan Tissue Engineering Co stock overvalued right now?
Based on GuruFocus' analysis, Japan Tissue Engineering Co (TSE:7774) is currently considered Modestly Overvalued. The stock's GF Value™ is 円517.18, compared to a current price of 円630.00 — trading 21.8% above its estimated fair value. The current Gross Margin % is 61.20%, which is near median its 10-year median of 57.70 and 0.5% above the Biotechnology industry median of 60.91. Japan Tissue Engineering Co's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Japan Tissue Engineering Co (TSE:7774), the current Gross Margin % is 61.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Japan Tissue Engineering Co (TSE:7774) Overvalued in 2026?
Based on GuruFocus' analysis, Japan Tissue Engineering Co stock appears to be overvalued.
The current stock price of 円630.00 is trading 21.8% above its estimated GF Value™ of 円517.18.
GuruFocus considers Japan Tissue Engineering Co to be Modestly Overvalued.
Key valuation signals for TSE:7774:
Gross Margin %: 61.20% (near median its 10-year median of 57.70)
GF Value™: 円517.18 vs. price of 円630.00 (21.8% above fair value)
Industry Position: 0.5% above the Biotechnology median (#384 of 730)
No single metric tells the full story. See the TSE:7774 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Japan Tissue Engineering Co Ltd is a bio-venture enterprise. It is engaged in the development, manufacture, and sale of tissue-engineered medical products and related products. It operates through the Regenerative Medicine, and Research and Development support business segments. The main business goal is to use autologous culturing techniques to develop tissue-engineered medical products and then to manufacture and sell these same tissue-engineered products to medical institutions for medical treatment. The company's tissue-engineered medical products are used in autologous transplant cases, where living cells are taken from the actual patient himself, cultured and then transplanted back to that same patient.
60GF Score
Get the complete analysis for TSE:7774
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7774 has been successfully added to your 
